<DOC>
	<DOCNO>NCT01933347</DOCNO>
	<brief_summary>The purpose study evaluate disease control rate ( DCR ) gefitinib third-line retreatment stage IIIB/IV NSCLC EGFR 19del/L858R positive mutation patient benefit first-line gefitinib treatment EGFR 19del/L858R positive mutation tumor progression second-line chemotherapy</brief_summary>
	<brief_title>Third-line Treatment Gefitinib NSCLC Patients</brief_title>
	<detailed_description>- Primary Study Objective : To evaluate disease control rate ( DCR ) gefitinib third-line retreatment stage IIIB/IV NSCLC EGFR 19del/L858R positive mutation patient benefit first-line gefitinib treatment EGFR 19del/L858R positive mutation tumor progression second-line chemotherapy - Secondary Study Objectives : To evaluate objective response rate ( ORR ) , progressive-free survival ( PFS ) , overall survival ( OS ) quality life ( QoL ) gefitinib third-line retreatment NSCLC patient To evaluate safety gefitinib third-line treatment NSCLC patient - Exploratory analysis : To dynamically monitor EGFR mutation status explore relationship clinical outcome</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>1 . The subject legal guardian could understand sign inform consent form . 2 . Male female age 18 year old ; 3 . Subjects diagnose stage IIIB IV NSCLC start first dose gefitinib thirdline treatment ; 4 . EGFR exon 19 deletion exon 21 L858R substitution mutation confirm ; 5 . ECOG performance status 02 ; 6 . Life expectancy least 12 week longer ; 7 . Has least one measureable lesion RECIST 1.1 ; 8 . NSCLC enrol subject previously progress firstline gefitinib treatment ( PFS ≥ 6 month ) progress secondline chemotherapy ( limited chemotherapy regimen , ≥ 4 cycle chemotherapy ) . Investigator consider adopt thirdline gefitinib retreatment ; 9 . Criteria laboratory examination : Total bilirubin ( TB ) ≤ 1.5 time upper limit normal Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) ≤2 time upper limit normal ; subject hepatic metastasis , AST , ALT≤ 5 time upper limit normal Creatinine clearance≥45ml/min 1 . Known severe hypersensitivity gefitinib ingredient product ; 2 . Patients prior exposure agent direct EGFR axis except gefitinib ( e.g . erlotinib , cetuximab , trastuzumab ) ; 3 . Preexisting interstitial lung disease pulmonary fibrosis evidence CT scan baseline ; 4 . Neutrophil count &lt; 1.0×109/L platelet count &lt; 50×109/L ; 5 . Severe infection , uncontrolled systemic disease ( e.g cardiopulmonary insufficiency , fatal arrhythmia , hepatitis , etc ) ; 6 . Pregnancy breastfeeding ; 7 . Women childbearing age refuse take adequate contraception measure gefitinib treatment 8 . Subjects malignant tumor combine ; 9 . Known suspected brain metastasis spinal cord compression , unless treat surgery and/or radiation stable without steroid treatment least 4 week prior first dose study medication ; 10 . Subjects unable take medication orally digestive malabsorption ; 11 . Investigators consider subject involve study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>